The global Interleukin IL market is anticipated to grow at a significant CAGR during the forecast period. The rising autoimmune diseases, improved Interleukin-IL inhibitors, and advancements in healthcare and research are all driving the global Interleukin-IL inhibitors market. Over the last few decades, there has been a significant paradigm shift in the treatment of autoimmune diseases owing to its improved safety and efficacy profiles, targeted therapies are becoming more popular. Patent expiration and increased biosimilar adoption in Tumor Necrosis Factor (TNF) inhibitors have increased the market's growth potential. New product launches are significant growth drivers in the rendering industry. The upcoming launches of late-stage pipeline candidates are expected to drive demand. Label expansions of already-marketed products, such as Actemra for juvenile idiopathic arthritis and Dupixent for atopic dermatitis, are expected to boost penetration even further. Furthermore, positive results from ongoing clinical trials indicate that the IL inhibitors market has high growth potential. As per the American Cancer Society in February 2022, the number of Castleman Disease (CD) cases in the US has increased from 4,300 to 5,100.

Impact of COVID-19 Pandemic on Global Interleukin IL Market

The COVID-19 pandemic has impacted the global economy due to a slowdown in the manufacturing of various industries. However, with its demands to treat severe pneumonia and alveolar damage, the virus had fueled the market for Interleukin-IL inhibitors. Tocilizumab and Sarilumab were used against COVID-19, and siltuximab was being studied. For instance, in July 2021, The World Health Organization (WHO) updated its patient care guidelines to include interleukin-6 receptor blockers, a class of medicines that are lifesaving in patients who are severely or critically ill with COVID-19, especially when administered alongside corticosteroids. These were the findings from a perspective and a living network meta-analysis initiated by WHO, the largest such analysis on the drugs to date. Data from over 10,000 patients enrolled in 27 clinical trials were considered.

Segmental Outlook 

The global Interleukin IL market is segmented based on type and application. Based on the type, the market is segmented into IL-17, IL-23, IL-1, IL-5, IL-6, and others. Based on application the market is sub-segmented into rheumatoid arthritis, asthma, inflammatory bowel disease, cancer, and others. The other type is segmented to Psoriasis. Based on application, Psoriasis has the major market share while based on type, IL-6 is projected to grow fastest during the forecast period.   

Global Interleukin IL Market Share by Application, 2021 (%)

The Psoriasis Segment is Anticipated to Hold a Prominent Share in the Global Interleukin IL Market

Psoriasis is one of the most common chronic skin diseases, and its prevalence is expected to rise with age. The primary factors driving the psoriasis segment growth are rising disease prevalence, increased consumer awareness, and favorable reimbursement policies. Stelara, Cosentyx, Siliq, and Taltz are some of the FDA-approved interleukin inhibitors for the treatment of psoriasis. According to the International Federation of Psoriasis Associations, more than 125 million people worldwide have psoriasis. Furthermore, people with psoriasis are more likely to develop co-morbidities such as diabetes and cardiovascular disease. The impact on mental health can be significant as well. Over the forecast period, demand for interleukin inhibitors is likely to rise in order to prevent such psoriasis-related co-morbidities. For instance, in 2020, UCB announced that the US Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for bimekizumab (UCB) for the treatment of moderate to severe plaque psoriasis in adults. As a result of the foregoing factors, it is expected to drive market growth in the near future.

Regional Outlooks

The global Interleukin IL market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America).  The Asia-Pacific regional Interleukin IL market is expected to hold a prominent market share due to the presence of several key market players.

Global Interleukin IL Market Growth, by Region 2022-2028

The Asia-Pacific Region Holds the Major Share in the Global Interleukin IL Market

The Asia-Pacific holds a prominent share in the market owing to an increase in the purchasing power of consumers, preference for healthy drinks over sugary drinks, and higher adoption of a healthy lifestyle among individuals. Owing to the growing trend, many manufacturers have started redefining products and appliances and are engaged in selling them through an online channel as well as stores. For instance; Aldi Australia brings back its hugely-popular portable blender again in January 2022, after shoppers purchased the gadget that was sold out in one day in 2019. The blender is a rechargeable, portable number, and Australian local stores have been cleaned out of the blender in an unforeseen fruit juice frenzy as it went on sale.

Market Players Outlook

The major companies serving the global Interleukin IL market include Johnson & Johnson Services, Inc., Novartis AG; AbbVie Inc., Eli Lilly & Co., Regeneron Pharmaceuticals, Inc., AstraZeneca; Bausch Health, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Teva Pharmaceuticals Industries, Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in 2019, Skyrizi (risankizumab-rzaa) was introduced by AbbVie, Inc. for the treatment of plaque psoriasis. Sun Pharmaceutical Industries Inc. previously introduced Ilumya (tildrakizumab-asmn) for moderate-to-severe plaque psoriasis.

The Report Covers

• Market value data analysis of 2022 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Interleukin IL market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.